Amphista Therapeutics, the spin out company from the lab of Professor Alessio Ciulli, was awarded the ‘Financing Deal of the Year’ award 2021 at the Scrip Awards last month. This was in recognition of their $53M Series B funding. The…
Our review on building and hijacking ubiquitination machineries by PROTACs and glues is now out in Current Opinion in Structural Biology Congratulations to Sarath on this review article. We hope people will find it useful! Read the Open Access full…
Our review covering E3 ligase ligands for PROTACs is now published in SLAS Discovery Congratulations to Tasuku on this article. We hope people will find this review useful! Read the Open Access full article. Authors: Tasuku Ishida and Alessio Ciulli*…
Our review on synthetic medicinal chemistry of phosphotyrosine analogues and phosphomimetics is now published in RSC Medicinal Chemistry. Congratulations to Nikolai on this comprehensive timely review. Hope people find this useful! Read the Open Access full article. Authors: Nikolai Makukhin…
Introducing BromoTAG and AGB1: our new inducible degron system for potent, rapid, selective protein degradation Great work by Adam and Conner, who led chemistry and biology on this study, and in collaboration with Dario Alessi’s group! Read the Open Access full article. Authors: Adam G.…
Our paper on the stereoselective synthesis of bumped BET bromodomain ligands has been selected for the front cover of Organic & Biomolecular Chemistry, Issue 38! The cover image was designed by Jagoda Sadowska, Alessio Ciulli and Adam Bond, and produced by Jagoda…
Well done to David – great job on this chapter! Read the chapter. Authors: David Zollman, Alessio Ciulli* Title: Structural and Biophysical Principles of Degrader Ternary Complexes Abstract Small-molecule degraders are a revolutionary modality of pharmacological intervention in chemical biology…
This new collaboration between Almirall and the group of Prof. Alessio Ciulli at Dundee University aims to discover and develop a class of small-molecule degrader drugs as a novel therapeutic paradigm to treat inflammatory skin diseases with unmet medical needs. …
Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and disease-relevant processes are well-characterized small chemical modulators of protein…
Our new paper describing stereoselective syntheses of allele-selective BET inhibitors bumped-JQ1 is now out in the RSC journal Org. Biomol. Chem. Congratulations to Adam and Andrea, on their development of this new route to synthesise the compounds! Read the Open…